News

Healthcare investor SHS Capital invests in Basic Pharma, a Dutch speciality pharmaceutical platform and full-service CDMO headquartered in Geleen. The investment provides a succession solution for the founder and aims to develop Basic Pharma into a leading European speciality pharma and dossier development platform for nasal sprays. Founded in 2003 by pharmacist Bob Kool, Basic […]

Tübingen / Warngau, 5 March 2026 Healthcare specialist SHS Capital with the other shareholders exits AMW, while SHS Capital is reinvesting with the current fund to continue the successful partnership. AMW is a German specialty pharma company focused on biodegradable controlled-release drug delivery systems. The transaction marks the continuation of a long-standing partnership, during which […]

The VICTORY trial was designed to compare the safety and efficacy of OPN NC against IVL, a widely used approach for managing heavily calcified lesions. The results indicate that OPN NC achieves comparable outcomes in this highly complex patient group, supporting its role as an effective alternative strategy for optimising stent deployment in challenging calcified […]

A study conducted at the University of Helsinki and Helsinki University Hospital has evaluated the performance of the MESI mTABLET TBI toe pressure photoplethysmography device against a stationary laser Doppler flow meter, the current gold standard for assessing superficial microvessels. The University of Helsinki study shows that the MESI mTABLET TBI demonstrates high concordance with […]

TRI has expanded its matrix® ecosystem with the matrix® X-Force implant, a line extension designed for immediacy and high primary stability, and currently available exclusively in the United States. The X-Force implant is positioned to support immediate protocols and challenging clinical indications where strong initial fixation is required, while retaining compatibility with the broader matrix® […]

AMW GmbH, a pharmaceutical company specialising in biodegradable implants, has initiated a research and development project aimed at increasing the efficiency of formulation development through the use of AI. The project is being scientifically supported by the research group of Prof. Dr. Olivia Merkel (LMU Munich), an expert in the field of drug delivery. The […]

Salvia is developing MySalvia Therapy, a personalised neuromodulation treatment designed to reduce the frequency and intensity of migraine attacks through a minimally invasive implant approach. The company positions the therapy as an alternative for patients who remain inadequately served by current preventive treatments, particularly given high discontinuation rates reported for existing migraine medications. The Series […]

Healthcare Specialist SHS Capital agreed to sell its portfolio company PathoQuest, a specialist in NGS-based quality control assays for biopharmaceuticals, to the strategic buyer Charles River Laboratories, a leading global provider of products and services that support drug discovery and non-clinical development. Founded in Paris, PathoQuest has established itself as a reference player in NGS-based […]

Tübingen / Kaltenkirchen / Illmensee, 17 December 2025 SHS Capital invests through its SHS VI fund in a consortium of four German medical technology companies focused on endoscopy systems, comprising EMOS Technology, InnoView, ILO electronic and Micon. The Endoscopy Group develops and manufactures high-quality, reusable flexible, rigid and semi-flexible endoscopes as well as camera and […]

Tübingen, 25 November 2025 SHS Capital, together with its portfolio company MTR, has acquired Curatec Services GmbH, an established provider of innovative electrical stimulation devices. The aim of the transaction is to secure Curatec’s proven expertise and product range for the long term, expand it within the MTR platform, and ensure that patients throughout Germany […]

We’re delighted to see the regional press Schwäbische highlighting our recent partnership with Ackermann. Another great example of how SHS Capital supports entrepreneurs when succession within the family isn’t an option. Together, we’ve created a solution that safeguards the company’s legacy, drives future growth, and keeps its values at the heart of the business. As […]

We are delighted that the new product RoTecPSMA® from our portfolio company ROTOP has received marketing authorisation in the UK. RoTecPSMA® is a diagnostic kit that uses technetium-99m and has been specially developed for SPECT imaging in prostate cancer patients. It is the first PSMA SPECT tracer to be approved in a European country. It […]